Price
1,664.1
-11.96%52W Range
Market Cap
₹3,892.67 Cr
Traded: ₹78.95 Cr (2.03%) 0.0x
Free Float: ₹731.82 Cr (10.79% of FF traded)
Volume · 60D trend
4.6 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +11.0% | +6.0% | -- | +41.0% | Stable |
| ROE | -- | +8.0% | +4.0% | -- | -- | Decelerating |
| Return | -- | -- | -5.0% | +53.0% | -- | Accelerating |
| Profit | -- | -4.0% | -5.0% | -- | +632.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Sep 2026PDF ↗ | Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 217 | 167 | 134 | 131 | 124 | 117 | 108 | 86 | 83 | 105 | 98 | 84 | 97 | 114 | 125 | 121 |
| Expenses | 177 | 135 | 106 | 106 | 101 | 100 | 99 | 79 | 78 | 93 | 83 | 73 | 76 | 93 | 108 | 103 |
| Operating Profit | 41 | 32 | 28 | 25 | 22 | 17 | 9 | 7 | 6 | 13 | 16 | 11 | 20 | 21 | 16 | 18 |
| Other Income | 2 | 1 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 5 | 1 | 1 | 1 | -3 | 1 |
| Interest | 3 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 2 |
| Depreciation | 11 | 11 | 10 | 9 | 9 | 9 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | 6 | 3 | 2 |
| Profit Before Tax | 29 | 21 | 17 | 18 | 14 | 9 | 2 | 0 | -1 | 7 | 14 | 5 | 11 | 13 | 8 | 14 |
| Tax % | 26.0% | 24.0% | 38.0% | 14.0% | 27.0% | 27.0% | 49.0% | -165.0% | -34.0% | 24.0% | 30.0% | 34.0% | 31.0% | 29.0% | -117.0% | 18.0% |
| Net Profit | 21 | 16 | 10 | 15 | 10 | 7 | 1 | 0 | -1 | 5 | 10 | 3 | 8 | 10 | 17 | 12 |
| Exceptional Items | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4 | 0 |
| EPS (Rs) | 9.2 | 6.8 | 4.4 | 6.5 | 4.2 | 2.8 | 0.4 | 0.1 | -0.3 | 2.2 | 4.1 | 1.5 | 3.3 | 4.3 | 7.7 | 5.2 |
| Sales Growth (YoY) | 76.0% | 43.0% | 24.0% | 53.0% | 48.0% | 11.0% | 10.0% | 2.0% | -14.0% | -8.0% | -21.0% | -30.0% | 7.0% | -- | -- | -- |
| Sales Growth (QoQ) | -- | 24.6% | 2.3% | 5.7% | 6.0% | 8.3% | 25.6% | 3.6% | -20.9% | 7.1% | 16.7% | -13.4% | -14.9% | -8.8% | 3.3% | -- |
| OP Growth (YoY) | 86.4% | 88.2% | 211.1% | 257.1% | 266.7% | 30.8% | -43.8% | -36.4% | -70.0% | -38.1% | 0.0% | -38.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | 28.1% | 14.3% | 12.0% | 13.6% | 29.4% | 88.9% | 28.6% | 16.7% | -53.8% | -18.8% | 45.5% | -45.0% | -4.8% | 31.3% | -11.1% | -- |
| Profit Growth (YoY) | 116.0% | 155.0% | 902.0% | 10736.0% | 1603.0% | 28.0% | -89.0% | -96.0% | -108.0% | -45.0% | -53.0% | -70.0% | 9.0% | -3.0% | 17.0% | -49.0% |
| EPS Growth (YoY) | -- | 140.5% | 902.3% | 10716.7% | 1614.3% | 27.4% | -89.3% | -96.0% | -108.4% | -48.0% | -46.3% | -71.8% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 54.9% | -32.0% | 53.1% | 49.3% | 545.5% | 633.3% | 121.4% | -112.6% | -45.7% | 177.7% | -55.6% | -22.4% | -43.9% | 46.0% | -- |
| OP Margin | -- | 19.2% | 20.9% | 19.1% | 17.7% | 14.5% | 8.3% | 8.1% | 7.2% | 12.4% | 16.3% | 13.1% | 20.6% | 18.4% | 12.8% | 14.9% |
| Net Margin | -- | 9.6% | 7.5% | 11.4% | 8.1% | 6.0% | 0.9% | 0.0% | -1.2% | 4.8% | 10.2% | 3.6% | 8.3% | 8.8% | 13.6% | 9.9% |
| Material Cost % | 48.9% | 45.1% | 41.9% | 42.0% | 44.4% | 49.9% | 53.5% | 48.4% | 51.2% | 54.0% | 42.2% | 44.3% | 38.6% | 50.8% | 60.2% | 56.2% |
| Employee Cost % | 8.4% | 10.0% | 12.7% | 12.8% | 12.1% | 12.1% | 13.0% | 15.4% | 15.5% | 12.0% | 14.6% | 15.7% | 14.6% | 10.1% | 10.4% | 8.7% |
| P/S | 5.99 | 8.01 | 6.56 | 6.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 61.86 | 86.64 | 78.88 | 93.95 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.78 | 5.70 | 4.25 | 4.08 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper Publication of Extract of Financial Results of the Company for the quarter and half year ended 30 September 2026.
Updated Investor Presentation.
Investor Presentation for the quarter and half year ended 30 September 2026.
Earnings Call scheduled to be held on Monday, 19 October 2026 at 05:00 p.m. (IST) has been cancelled due to unforeseen circumstances.
Outcome Of the Board Meeting Held On 19.10.2026
Enclosed
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Earnings Call post announcement of ....
Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/10/2026 ,inter alia, to consider and approve and take on record ....
Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation of Credit Rating
Newspaper Advertisement - Disclosure under Regulation 30, 44 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as ....
Intimation of Record Date, Book Closure and Cut-Off Date pursuant to Regulation 42 and 44 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) ....
Pursuant to Regulation 34(2)(f) of the SEBI Listing Regulations, we are submitting herewith the Business Responsibility and Sustainability Report (BRSR") for FY 2025-26 which forms part ....
Pursuant to Regulation 34(1) of the SEBI Listing Regulations, please find enclosed herewith the Annual Report of the Company along with the Notice of the 30th Annual General Meeting ('AGM') ....
Notice of the 30th AGM of the Members of the Company scheduled to be held on Friday, 25 September 2026 at 4:00 p.m. (IST) through Video Conferencing (''VC") / Other Audio Visual Means ("OAVN")
Resignation of a Senior Management Personnel of the Company.
Newspaper Advertisement - Disclosure under Regulation 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. ....
Communication to Shareholders - Final Dividend for FY 2025-26 - Intimation on Tax Deduction at source (TDS) / withholding tax on Dividend
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Newspaper Publication of Extract of Financial Results of the Company for the quarter ended 30 June 2026.
Link of Audio Recording of the Earnings call held on Friday, 17July 2026 at 05:00 p.m. (IST) is attached.
Investor Presentation for the quarter ended 30 June 2026.
Enclosed herewith intimation regarding Capacity Addition.
Detailed disclosure is enclosed.
Enclosed
Outcome Of The Board Meeting Held On 17.07.2026.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Earnings Call post announcement of ....
Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/07/2026 ,inter alia, to consider and approve and take on record ....
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Transcript of the earnings call held on 16 May 2026 post announcement of the financial results of the Company for the quarter and financial year ended 31 March 2026.
Submission of Annual Secretarial Compliance Report for the financial year ended 31 March 2026 (2025-2026).
Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Financial Year ended 31 March 2026.
Link of Audio Recording of the Earning call held on Saturday, 16 May 2026 at 05:00 p.m. (IST) is attached.
Investor Presentation for the quarter and financial year ended 31 March 2026.
Re-appointment of Cost Auditor and Internal Auditor
Outcome of Board Meeting - Board approves Dividend
Outcome Of The Board Meeting Held On 16.05.2026
Enclosed
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Earnings Call post announcement of ....
Credit Ratings
6Concalls
19Jan 2026
31 Jan 2026Nov 2025
30 Nov 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Oct 2024
31 Oct 2024Jul 2024
31 Jul 2024May 2024
31 May 2024Jan 2024
31 Jan 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Jan 2023
31 Jan 2023Nov 2022
30 Nov 2022Jul 2022
31 Jul 2022Apr 2022
30 Apr 2022Jan 2022
31 Jan 2022Oct 2021
31 Oct 2021Sep 2021
30 Sept 2021Held by Mutual Funds
6 schemes hold tatva · sorted by weight